carmustine has been researched along with Breast Neoplasms in 117 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We assessed the 5-year results of a high-dose cyclophosphamide, carmustine, and thiotepa (CBT) regimen plus autologous hematopoietic stem cell transplantation (AHST) as an adjuvant consolidation therapy for high-risk primary breast cancer patients with > or =10 positive axillary lymph nodes after primary surgery or > or =4 positive axillary lymph nodes after neoadjuvant chemotherapy and surgery." | 9.11 | The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. ( Champlin, RE; Cheng, YC; Donato, ML; Gajewski, JL; Hortobagyi, GN; Jones, R; Rondón, G; Shpall, EJ; Smith, TL; Ueno, NT; Yang, Y, 2004) |
| "Doxorubicin plus paclitaxel has been shown to be an active regimen for metastatic breast cancer and is now frequently used as adjuvant therapy for high-risk primary breast cancer." | 9.09 | Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer. ( Abella, E; Baynes, RD; Cassells, L; Dansey, RD; Du, W; Hamm, C; Karanes, C; Klein, JL; Peters, WP; Rey, PM, 2000) |
| "A total of 54 breast cancer patients receiving high-dose cyclophosphamide, cisplatin and carmustine were treated prospectively in four sequential cohorts." | 9.08 | Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. ( Berry, D; Cavanaugh, C; Fehdrau, R; Gilbert, CJ; Hussein, A; McKinstry, C; Peters, WP; Petros, WP; Ross, M; Rubin, P; Vredenburgh, J, 1998) |
| "Since 1999, patients presenting with brain metastases (BM) from breast cancer (BC) are treated in our institution with a carmustine (BCNU)--methotrexate (MTX) combination." | 7.76 | Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. ( About, M; Gerlotto-Borne, MC; Jacot, W; Pouderoux, S; Poujol, S; Romieu, G; Thezenas, S, 2010) |
| "The syndrome of retinal vascular occlusion, optic neuropathy, and myelopathy is associated with the high-dose chemotherapeutic agents carmustine and cisplatin." | 7.70 | Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. ( Arnold, AC; Glasgow, BJ; Vinters, HV; Wang, MY, 2000) |
| "We describe seven patients who developed symptoms including severe headache, circumoral paresthesia, and facial flushing during high-dose carmustine (BCNU) infusion as part of the preparative regimen for autologous peripheral blood stem cell (PBSC) transplantation for metastatic breast cancer." | 7.69 | Headache, circumoral paresthesia, and facial flushing associated with high-dose carmustine infusion. ( Bruton, J; Champlin, R; Ippoliti, C; Mehra, R; Przepiorka, D; Woo, MH, 1997) |
| "MCF-7 human breast cancer cells possess high levels of O6-alkylguanine-DNA alkyltransferase and moderate levels of glutathione, and are more resistant to chloroethylnitrosoureas (CNUs) than cells with low levels of either molecule." | 7.69 | Combined depletion of O6-alkylguanine-DNA alkyltransferase and glutathione to modulate nitrosourea resistance in breast cancer. ( Berger, SJ; Donovan, C; Gerson, SL; Varnes, ME, 1994) |
| "The results of treatment with 5-fluorouracil, imidazole carboxamide, BCNU and prednisolone (FIB-P) salvage chemotherapy in 60 patients with heavily pretreated advanced breast cancer are presented." | 7.68 | Combination of 5-fluorouracil, imidazole carboxamide, BCNU and prednisolone (FIB-P) as a salvage chemotherapy in heavily pretreated breast cancer patients. ( Cerar, O; Cervek, J; Cufer, T; Kolaric, K, 1992) |
| "Eighty-five women with primary breast cancer involving >or=10 lymph nodes received four cycles of standard-dose chemotherapy followed by a high-dose regimen consisting of: cyclophosphamide (1875 mg/m(2) once daily x 3), cisplatin (165 mg/m(2) given over 72 h), carmustine (600 mg/m(2)), and stem cell transplantation." | 6.70 | Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. ( Berry, D; Broadwater, G; Colvin, OM; Gibbs, JP; Gilbert, CJ; Jones, RB; Peters, WP; Petros, WP; Vredenburgh, JJ, 2002) |
| "Triple-negative breast cancer is characterized by aggressive tumours whose cells lack oestrogen and progesterone receptors and do not over-express HER2." | 5.39 | Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells. ( Adams, C; Cazzanelli, G; Coombes, C; Hu, Y; Masrour, N; Papoutsoglou, P; Patel, N; Raguz, S; Rasul, S; Yagüe, E; Zhou, Y, 2013) |
| "We treated MCF-7 breast cancer cells three times with cytotoxic concentrations of BG + BCNU to isolate a population of MCF-7 cells possessing BG + BCNU resistance (BBR)." | 5.30 | Acquired resistance to O6-benzylguanine plus chloroethylnitrosoureas in human breast cancer. ( Gerson, SL; Phillips, WP, 1999) |
| "We assessed the 5-year results of a high-dose cyclophosphamide, carmustine, and thiotepa (CBT) regimen plus autologous hematopoietic stem cell transplantation (AHST) as an adjuvant consolidation therapy for high-risk primary breast cancer patients with > or =10 positive axillary lymph nodes after primary surgery or > or =4 positive axillary lymph nodes after neoadjuvant chemotherapy and surgery." | 5.11 | The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. ( Champlin, RE; Cheng, YC; Donato, ML; Gajewski, JL; Hortobagyi, GN; Jones, R; Rondón, G; Shpall, EJ; Smith, TL; Ueno, NT; Yang, Y, 2004) |
| "Seven hundred eighty-five women aged 22 to 66 years with stage IIA, IIB, or IIIA breast cancer involving 10 or more axillary lymph nodes were randomized after surgery and standard adjuvant chemotherapy to either high-dose cyclophosphamide, cisplatin, and carmustine (HD-CPB) with stem-cell support or intermediate-dose cyclophosphamide, cisplatin, and carmustine (ID-CPB) with G-CSF support but without stem cells." | 5.11 | Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA ( Cirrincione, C; Crump, M; Henderson, IC; Hurd, DD; Marks, LB; Norton, L; Peters, WP; Richardson, PG; Rosner, GL; Schilsky, RL; Schuster, MW; Shpall, EJ; Vredenburgh, JJ, 2005) |
| "Doxorubicin plus paclitaxel has been shown to be an active regimen for metastatic breast cancer and is now frequently used as adjuvant therapy for high-risk primary breast cancer." | 5.09 | Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer. ( Abella, E; Baynes, RD; Cassells, L; Dansey, RD; Du, W; Hamm, C; Karanes, C; Klein, JL; Peters, WP; Rey, PM, 2000) |
| "A total of 54 breast cancer patients receiving high-dose cyclophosphamide, cisplatin and carmustine were treated prospectively in four sequential cohorts." | 5.08 | Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. ( Berry, D; Cavanaugh, C; Fehdrau, R; Gilbert, CJ; Hussein, A; McKinstry, C; Peters, WP; Petros, WP; Ross, M; Rubin, P; Vredenburgh, J, 1998) |
| "We studied high-dose cyclophosphamide, cisplatin, and carmustine (CPA/cDDP/BCNU) with autologous bone marrow support (ABMS) as consolidation after standard-dose adjuvant chemotherapy treatment of primary breast cancer involving 10 or more axillary lymph nodes." | 5.07 | High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. ( Bast, RC; Jones, R; Kurtzberg, J; Marks, LB; Meisenberg, B; Peters, WP; Ross, M; Shpall, E; Vredenburgh, JJ; Winer, E, 1993) |
| "Since 1999, patients presenting with brain metastases (BM) from breast cancer (BC) are treated in our institution with a carmustine (BCNU)--methotrexate (MTX) combination." | 3.76 | Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. ( About, M; Gerlotto-Borne, MC; Jacot, W; Pouderoux, S; Poujol, S; Romieu, G; Thezenas, S, 2010) |
| "A genotype association study was conducted on 85 chemotherapy-naïve patients with metastatic or inflammatory breast cancer that were evaluated for an extended period after receiving standard-dose chemotherapy followed by high-dose cyclophosphamide, cisplatin, and carmustine." | 3.73 | Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. ( Broadwater, G; Colvin, OM; Hall, J; Hopkins, PJ; Jones, RB; Marks, JR; Peters, WP; Petros, WP; Spruill, S; Vredenburgh, JJ, 2005) |
| "Delayed pulmonary toxicity syndrome, characterized by interstitial pneumonia and pulmonary fibrosis, is common following high-dose bischloroethylnitrosourea (BCNU) (carmustine, [1,3-bis (2-chloroethyl)-1-nitrosourea]) containing chemotherapeutic regimens." | 3.72 | Interferon-gamma for delayed pulmonary toxicity syndrome resistant to steroids. ( Brown, KK; Cool, CD; Jones, RB; Lynch, DA; Suratt, BT, 2003) |
| "Our aim was to describe the incidence, clinical course, and risk factors for idiopathic pneumonia syndrome (IPS) after high-dose chemotherapy with cyclophosphamide, carmustine, and thiotepa followed by autologous stem cell transplantation for high-risk breast cancer." | 3.72 | Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. ( Champlin, RE; Giralt, SA; Rondon, G; Saliba, RM; Shannon, VR; Ueno, NT; Wong, R, 2003) |
| "Eight patients with advanced breast cancer were entered into a prospective, longitudinal trial that included examination by MR imaging and proton MR spectroscopy before chemotherapy and through 12 months after treatment with carmustine, cyclophosphamide, and cisplatin, combined with autologous hematopoietic progenitor cell support (AHPCS)." | 3.70 | White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. ( Brown, MS; Cagnoni, PJ; Jones, RB; Sheeder, JL; Simon, JH; Stears, JC; Stemmer, SM, 1998) |
| "A preliminary analysis of our double high-dose chemotherapy with stem cell rescue (HD-SCR) clinical trial for breast cancer, and preclinical cross-resistant studies, suggested that melphalan (M) adversely affected response to subsequent chemotherapy, i." | 3.70 | Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence. ( Ara, G; Bunnell, C; Elias, A; Frei, E; Richardson, P; Teicher, B; Tew, K; Wheeler, C, 2000) |
| "The syndrome of retinal vascular occlusion, optic neuropathy, and myelopathy is associated with the high-dose chemotherapeutic agents carmustine and cisplatin." | 3.70 | Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. ( Arnold, AC; Glasgow, BJ; Vinters, HV; Wang, MY, 2000) |
| "Thirteen patients with high-risk stage II or stage IV breast cancer treated with high-dose cyclophosphamide, cisplatin, carmustine, and bone marrow support underwent posttransplant MR examination of the brain." | 3.69 | White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. ( Burton, BS; Jones, RB; Simon, JH; Stears, JC; Stemmer, SM, 1994) |
| "MCF-7 human breast cancer cells possess high levels of O6-alkylguanine-DNA alkyltransferase and moderate levels of glutathione, and are more resistant to chloroethylnitrosoureas (CNUs) than cells with low levels of either molecule." | 3.69 | Combined depletion of O6-alkylguanine-DNA alkyltransferase and glutathione to modulate nitrosourea resistance in breast cancer. ( Berger, SJ; Donovan, C; Gerson, SL; Varnes, ME, 1994) |
| "We describe seven patients who developed symptoms including severe headache, circumoral paresthesia, and facial flushing during high-dose carmustine (BCNU) infusion as part of the preparative regimen for autologous peripheral blood stem cell (PBSC) transplantation for metastatic breast cancer." | 3.69 | Headache, circumoral paresthesia, and facial flushing associated with high-dose carmustine infusion. ( Bruton, J; Champlin, R; Ippoliti, C; Mehra, R; Przepiorka, D; Woo, MH, 1997) |
| "Nine patients with advanced breast cancer were referred for visual symptoms after high-dose chemotherapy with cisplatin, cyclophosphamide, and carmustine and autologous bone marrow transplantation without total body irradiation or local head irradiation." | 3.69 | Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. ( Jaffe, GJ; Khawly, JA; Peters, WP; Petros, W; Rubin, P, 1996) |
| "Therapy with high-dose cyclophosphamide, cisplatin, and carmustine (BCNU) plus autologous bone marrow transplantation has been extensively studied as treatment for patients with stage II or III breast cancer who have a 70% or greater risk of developing metastatic disease." | 3.68 | Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. ( Bearman, SI; Dufton, C; Fisher, JH; Jones, RB; Matthes, S; Shpall, EJ; Stemmer, SM; Stephens, JK, 1993) |
| "Between 2/87 and 2/91, 49 women with operable breast cancer involving greater than or equal to 10 axillary nodes were treated following mastectomy, with four cycles of Cyclophosphamide, Adriamycin, 5FU, followed by high doses of Cyclophosphamide, Cisplatin, Carmustine (HDCT) with autologous bone marrow transplant support." | 3.68 | Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. ( Halperin, EC; Marks, LB; Peters, W; Prosnitz, LR; Rosner, GL; Ross, M; Vredenburgh, JJ, 1992) |
| "The results of treatment with 5-fluorouracil, imidazole carboxamide, BCNU and prednisolone (FIB-P) salvage chemotherapy in 60 patients with heavily pretreated advanced breast cancer are presented." | 3.68 | Combination of 5-fluorouracil, imidazole carboxamide, BCNU and prednisolone (FIB-P) as a salvage chemotherapy in heavily pretreated breast cancer patients. ( Cerar, O; Cervek, J; Cufer, T; Kolaric, K, 1992) |
| "21 patients with metastatic breast cancer, refractory to conventional agents, were treated with a combination of BCNU, vincristine, mitomycin-C and prednisone given every 4 weeks." | 3.67 | Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study. ( Anderson, P; DiBella, NJ; Fink, K; Garfield, D; Murphy, J; Speer, J, 1984) |
| "To evaluate the effect of high-dose chemotherapy in the treatment of metastatic breast cancer, we performed a phase II trial of a single treatment with high-dose cyclophosphamide (5,625 mg/m2), cisplatin (165 mg/m2), and carmustine (600 mg/m2), or melphalan (40 mg/m2) and bone marrow support as the initial chemotherapy for metastatic breast cancer." | 3.67 | High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. ( Bast, RC; Gockerman, JP; Jones, RB; Moore, JO; Olsen, GA; Peters, WP; Shpall, EJ, 1988) |
| "The five-drug combination of fluorouracil imidazole carboxamide dimethyl triazeno, vincristine, bis-chloroethyl nitrosourea, and prednisone (FIVB + P) was given to 120 women with metastatic breast cancer." | 3.66 | A five-drug combination in the treatment of metastatic breast cancer. ( Falkson, G; Falkson, HC, 1981) |
| " In the other five patients the regional superselective chemoinfusion was fulfilled successfully to the arteries feeding the metastatic foci in the brain with Carmustin in dosage 100 mg in combination with radiation therapy that was fulfilled in all six patients before the planned total focal dose." | 2.76 | [Regional chemoinfusion and radiation therapy to patients with breast cancer metastases to the brain: preliminary results]. ( Korytova, LI; Meshechkin, AV; Suvorova, IuV; Zhabina, RM, 2011) |
| " Two patients had severe adverse events thought to be related to wafer placement, one with seizures alone, and one with seizures and subsequent respiratory compromise." | 2.73 | Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. ( Brem, S; Carey, LA; Cush, S; Ewend, MG; Gilbert, M; Goodkin, R; Penar, PL; Varia, M, 2007) |
| "Incorporation of trastuzumab into HDC (cyclophosphamide, cisplatin, and BCNU) is feasible, with no apparent increased toxicity or pharmacokinetic interactions." | 2.71 | Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. ( Barón, AE; Bearman, SI; Chao, N; Gasparetto, C; Jones, RB; Matthes, S; McSweeney, PA; Nieto, Y; Rizzieri, D; Shpall, EJ; Vredenburgh, JJ, 2004) |
| "Despite modern chemotherapy, advanced breast cancer remains a significant cause of cancer morbidity and mortality in women." | 2.70 | High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes. ( Broadwater, G; Chao, NJ; Folz, RJ; Hussein, A; Long, GD; Marks, LB; Peters, WP; Rizzieri, D; Ross, M; Stuart, MJ; Vredenburgh, JJ, 2002) |
| "Eighty-five women with primary breast cancer involving >or=10 lymph nodes received four cycles of standard-dose chemotherapy followed by a high-dose regimen consisting of: cyclophosphamide (1875 mg/m(2) once daily x 3), cisplatin (165 mg/m(2) given over 72 h), carmustine (600 mg/m(2)), and stem cell transplantation." | 2.70 | Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. ( Berry, D; Broadwater, G; Colvin, OM; Gibbs, JP; Gilbert, CJ; Jones, RB; Peters, WP; Petros, WP; Vredenburgh, JJ, 2002) |
| " We reviewed the AUC of CPA in 470 patients who underwent pharmacokinetic monitoring of the drug." | 2.69 | Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Bearman, SI; Cagnoni, PJ; Jones, RB; Matthes, S; Murphy, J; Nieto, Y; Shpall, EJ; Xu, X, 1999) |
| "Early phase evaluation of anticancer drugs has traditionally used toxicity (usually hematological) rather than efficacy end points to establish appropriate dosing schedules." | 2.69 | O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. ( Gerson, SL; Haaga, J; Hoppel, CL; Ingalls, ST; Liu, L; Majka, S; Pluda, JM; Spiro, TP; Willson, JK, 1999) |
| "The prognosis for patients with primary breast cancer involving multiple axillary lymph nodes is poor." | 2.68 | Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II o ( Hurd, DD; Peters, WP, 1995) |
| " These data suggest that currently used filgrastim dosing strategies following autologous bone marrow transplantation may be suboptimal." | 2.68 | Clinical pharmacology of filgrastim following high-dose chemotherapy and autologous bone marrow transplantation. ( Peters, WP; Petros, WP; Rabinowitz, J; Stuart, A, 1997) |
| "Forty-three patients are alive and breast cancer-free at a median of 947 days (range 661-1730 days) after the start of therapy, including one patient who developed myelodysplastic syndrome 809 days after the start of HDCT." | 2.68 | High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. ( Barón, AE; Bearman, SI; Bolwell, BJ; Cagnoni, PJ; Jones, RB; Mechling, BE; Overmoyer, BA; Purdy, MH; Ronk, B; Ross, M; Shpall, EJ; Taylor, CW, 1997) |
| "No fatal complications or chronic pulmonary fibrosis was seen." | 2.68 | Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment. ( Chap, L; Glaspy, J; Levine, M; Lill, M; Norton, L; Shpiner, R, 1997) |
| "Patients with metastatic breast cancer (MBC) (median follow-up, 1." | 2.41 | High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California. ( Blume, KG; Cecchi, GR; Damon, LE; Glaspy, J; Gold, E; Hu, WW; Irwin, D; Linker, CA; Mason, JR; Miller, W; Stockerl-Goldstein, KE; Territo, I; Wolf, JL, 2000) |
| " Relatively little is known about the pharmacokinetic or pharmacodynamic aspects of their use." | 2.38 | Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer. ( Bearman, SI; Dufton, C; Jones, RB; Matthes, S; Meyers, S; Shpall, EJ; Stemmer, SM, 1993) |
| "In small cell lung cancer initial high dose therapy followed by non-cross-resistant regimens may prove effective." | 2.37 | High dose chemotherapy in solid tumours in adults. ( Peters, W; Souhami, R, 1986) |
| "Triple-negative breast cancer is characterized by aggressive tumours whose cells lack oestrogen and progesterone receptors and do not over-express HER2." | 1.39 | Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells. ( Adams, C; Cazzanelli, G; Coombes, C; Hu, Y; Masrour, N; Papoutsoglou, P; Patel, N; Raguz, S; Rasul, S; Yagüe, E; Zhou, Y, 2013) |
| " DTIC and AIC exhibited biphasic clearance from the blood, consistent with a 2-compartment pharmacokinetic model." | 1.32 | Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer. ( Clemons, M; El Teraifi, H; Griffiths, A; Howell, A; Kelly, J; Margison, GP; Margison, JM; Morris, CQ; Ranson, M, 2003) |
| "Bilateral upper lobe pulmonary fibrosis can be associated with chemotherapeutic drugs." | 1.32 | Upper lobe pulmonary fibrosis associated with high-dose chemotherapy containing BCNU for bone marrow transplantation. ( Leslie, KO; Muhm, JR; Parish, JM, 2003) |
| "All patients received similar anti-infection prophylaxis for 3 months after transplantation." | 1.32 | Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation. ( Amodeo, R; Anghel, G; De Rosa, L; Majolino, I; Pandolfi, A; Riccardi, M, 2004) |
| "The incidence of PTS in breast cancer patients treated with a BCNU-containing HDC regimen can be remarkably high." | 1.31 | Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. ( Blume, KG; Cao, TM; Hu, WW; Johnston, LJ; Negrin, RS; Rizk, NW; Shizuru, JA; Stockerl-Goldstein, KE; Taylor, TL; Wong, RM, 2000) |
| "The median time to disease progression and median survival were 1." | 1.31 | Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. ( Blume, KG; Chao, NJ; Feiner, RH; Hu, WW; Johnston, LJ; Long, GD; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, K; Wong, RM, 2000) |
| "We retrospectively evaluated 443 breast cancer patients treated with high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) with autologous stem cell support to characterize the cardiac toxicity of this regimen." | 1.31 | Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. ( Bearman, SI; Cagnoni, PJ; Jones, RB; Matthes, S; Nieto, Y; Shpall, EJ, 2000) |
| "Patients with high risk breast carcinoma were conditioned with high dose carmustine, cisplatin, and cyclophosphamide followed by autologous PSCT." | 1.30 | Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma. ( Chap, L; Hecht, JR; Lembo, T, 1997) |
| " infusion via an ambulatory infusion pump with patient-activated intermittent dosing (BAD pump) for prevention of acute and delayed nausea/vomiting in patients receiving high-dose chemotherapy (HDC) for peripheral blood progenitor cell (PBPC) mobilization (MOB) or prior to autologous PBPC rescue." | 1.30 | Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy. ( Belt, R; Coon, J; Cord, M; Dix, S; Geller, R; Howard, S, 1999) |
| "Twenty-six patients with breast cancer who had relapsed after previously receiving high-dose chemotherapy and autologous hematopoietic cell support received a second course of high-dose cytoreductive therapy and autologous hematopoietic cell support as salvage therapy." | 1.30 | High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy. ( Bearman, S; Cagnoni, P; Jones, R; Nieto, Y; Peters, W; Ross, M; Shpall, E; Vredenburgh, J, 1999) |
| "We treated MCF-7 breast cancer cells three times with cytotoxic concentrations of BG + BCNU to isolate a population of MCF-7 cells possessing BG + BCNU resistance (BBR)." | 1.30 | Acquired resistance to O6-benzylguanine plus chloroethylnitrosoureas in human breast cancer. ( Gerson, SL; Phillips, WP, 1999) |
| "We present a patient with metastatic breast cancer treated with high-dose chemotherapy and bone marrow transplantation." | 1.29 | Clostridium septicum abscess in hepatic metastases: successful medical management. ( Ciaccia, D; Corey, GR; Peters, W; Thel, MC; Vredenburgh, JJ, 1994) |
| "The phase I trial in breast cancer conducted by Peters et al." | 1.29 | Positive selection and ex vivo expansion of hematopoietic progenitors as autografts for high-dose chemotherapy, potential importance in patients with bone metastases. ( Purdy, MH, 1995) |
| "In the MCF-7 human breast cancer cell line and in the MCF-7/CP (CDDP resistant) subline, U73-975 and mitoxantrone were both potent cytotoxic agents (IC50 0." | 1.28 | Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells. ( Ayash, L; Herman, TS; Korbut, T; Teicher, BA, 1991) |
| "Hydroxyurea is an antineoplastic drug with a broad spectrum of clinical activity and minimal nonhematopoietic toxicity." | 1.28 | High-dose hydroxyurea in autologous bone marrow transplantation: a promising "new" agent. ( Armitage, JO; Bierman, PJ; Glenn, LD; Kessinger, A; Reed, EC; Vaughan, WP, 1992) |
| "Treatment with lonidamine increased the cytotoxicity of each drug by 1." | 1.28 | Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. ( Epelbaum, R; Frei, E; Herman, TS; Holden, SA; Liu, SD; Teicher, BA, 1991) |
| "Metronidazole, 1." | 1.27 | Feasibility study of combining metronidazole with chemotherapy. ( Bélanger, R; Crook, AF; Heringer, R; Hopkins, HS; Hugenholtz, H; Maroun, JA; Richard, MT; Stewart, DJ; Yan, RC; Young, V, 1983) |
| "Of 16 evaluable patients with breast cancer, 15 responded (six complete responses)." | 1.27 | High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. ( Andersen, J; Antman, K; Eder, JP; Elias, A; Finberg, R; Henner, WD; Peters, WP; Schryber, S; Shea, T; Wilmore, D, 1987) |
| " Log-linear tumor cell kill was also obtained over a wide dosage range with several alkylating agents in murine tumors treated in vivo." | 1.27 | Preclinical studies and clinical correlation of the effect of alkylating dose. ( Cathcart, KN; Frei, E; Holden, SA; Teicher, BA; Wang, YY, 1988) |
| "Seventeen patients with metastatic breast cancer were treated with a high-dose combination chemotherapy regimen and autologous bone marrow support." | 1.27 | High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. ( Andersen, J; Antman, K; Come, S; Eder, JP; Elias, A; Henner, WD; Peters, W; Schnipper, L; Schryber, S; Shea, T, 1986) |
| "Seven patients with metastatic tumors resistant to therapy with adriamycin, BCNU, plus cyclophosphamide received the same chemotherapy combined with amphotericin B." | 1.26 | Amphotericin B induction of sensitivity to adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) plus cyclophosphamide in human neoplasia. ( Klahr, C; Presant, CA; Santala, R, 1977) |
| "Four cases of breast cancer with meningeal involvement are presented and a review of the literature is given." | 1.26 | [(Meningeal carcinomatosis in patients with breast cancer)]. ( Freund, M; Ostendorf, P; Waller, HD, 1979) |
| "Osseous, visceral, and cutaneous metastases responded equally well." | 1.26 | Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC 409462), and cyclophosphamide in refractory adenocarcinoma of the breast and other tumors. ( Klahr, C; Kolhouse, JF; Presant, CA, 1976) |
| "Skin, lymph node, and soft tissue metastases more frequently responded to therapy, while hepatic, peritoneal, and osseous metastases responded with an intermediate frequency." | 1.26 | Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962) and cyclophosphamide therapy of drug-resistant metastatic breast carcinoma. ( Klahr, C; Presant, CA; Van Amburg, A, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (24.79) | 18.7374 |
| 1990's | 49 (41.88) | 18.2507 |
| 2000's | 30 (25.64) | 29.6817 |
| 2010's | 8 (6.84) | 24.3611 |
| 2020's | 1 (0.85) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, C | 1 |
| Rao, R | 1 |
| Cai, Z | 1 |
| Yang, H | 1 |
| Zhang, L | 1 |
| Ji, S | 1 |
| Zhang, C | 1 |
| Gao, D | 1 |
| Hu, Y | 2 |
| Li, J | 1 |
| Xiong, W | 1 |
| Jiang, H | 1 |
| Chu, J | 1 |
| Wu, D | 1 |
| Saha, P | 1 |
| Amico, AL | 1 |
| Olopade, OI | 1 |
| Theodossiou, TA | 1 |
| Olsen, CE | 1 |
| Jonsson, M | 1 |
| Kubin, A | 1 |
| Hothersall, JS | 1 |
| Berg, K | 1 |
| Sun, W | 2 |
| Kalen, AL | 1 |
| Smith, BJ | 2 |
| Cullen, JJ | 1 |
| Oberley, LW | 2 |
| Marks, LB | 5 |
| Cirrincione, C | 3 |
| Fitzgerald, TJ | 1 |
| Laurie, F | 1 |
| Glicksman, AS | 1 |
| Vredenburgh, J | 5 |
| Prosnitz, LR | 2 |
| Shpall, EJ | 15 |
| Crump, M | 2 |
| Richardson, PG | 2 |
| Schuster, MW | 3 |
| Ma, J | 1 |
| Peterson, BL | 1 |
| Norton, L | 3 |
| Seagren, S | 1 |
| Henderson, IC | 2 |
| Hurd, DD | 4 |
| Peters, WP | 16 |
| Stankiewicz-Kranc, A | 1 |
| Miltyk, W | 1 |
| Skrzydlewska, E | 1 |
| Jacot, W | 1 |
| Gerlotto-Borne, MC | 1 |
| Thezenas, S | 1 |
| Pouderoux, S | 1 |
| Poujol, S | 1 |
| About, M | 1 |
| Romieu, G | 1 |
| Singh, V | 1 |
| Devata, S | 1 |
| Cheng, YC | 2 |
| Meshechkin, AV | 1 |
| Korytova, LI | 1 |
| Zhabina, RM | 1 |
| Suvorova, IuV | 1 |
| Raguz, S | 1 |
| Adams, C | 1 |
| Masrour, N | 1 |
| Rasul, S | 1 |
| Papoutsoglou, P | 1 |
| Cazzanelli, G | 1 |
| Zhou, Y | 1 |
| Patel, N | 1 |
| Coombes, C | 1 |
| Yagüe, E | 1 |
| Clemons, M | 1 |
| Ranson, M | 1 |
| Margison, JM | 1 |
| El Teraifi, H | 1 |
| Griffiths, A | 1 |
| Kelly, J | 1 |
| Morris, CQ | 1 |
| Howell, A | 1 |
| Margison, GP | 1 |
| Stuart, MJ | 1 |
| Broadwater, G | 3 |
| Hussein, A | 2 |
| Ross, M | 8 |
| Folz, RJ | 1 |
| Long, GD | 2 |
| Rizzieri, D | 3 |
| Chao, NJ | 4 |
| Vredenburgh, JJ | 10 |
| Parish, JM | 1 |
| Muhm, JR | 1 |
| Leslie, KO | 1 |
| Suratt, BT | 1 |
| Lynch, DA | 1 |
| Cool, CD | 1 |
| Jones, RB | 18 |
| Brown, KK | 1 |
| Wong, R | 1 |
| Rondon, G | 3 |
| Saliba, RM | 1 |
| Shannon, VR | 1 |
| Giralt, SA | 2 |
| Champlin, RE | 3 |
| Ueno, NT | 3 |
| Gottfredsson, M | 1 |
| Xu, J | 1 |
| Schell, WA | 1 |
| Perfect, JR | 1 |
| De Rosa, L | 1 |
| Anghel, G | 1 |
| Pandolfi, A | 1 |
| Riccardi, M | 1 |
| Amodeo, R | 1 |
| Majolino, I | 1 |
| Stockerl-Goldstein, KE | 4 |
| Klein, J | 3 |
| Murphy, J | 4 |
| Blume, KG | 5 |
| Dansey, R | 3 |
| Martinez, C | 1 |
| Matthes, S | 7 |
| Nieto, Y | 8 |
| Yang, Y | 1 |
| Smith, TL | 1 |
| Gajewski, JL | 2 |
| Donato, ML | 2 |
| Jones, R | 3 |
| Hortobagyi, GN | 1 |
| Bearman, SI | 9 |
| McSweeney, PA | 1 |
| Chao, N | 1 |
| Gasparetto, C | 1 |
| Barón, AE | 3 |
| Rosner, GL | 2 |
| Schilsky, RL | 1 |
| Petros, WP | 5 |
| Hopkins, PJ | 1 |
| Spruill, S | 1 |
| Colvin, OM | 2 |
| Hall, J | 1 |
| Marks, JR | 1 |
| Peppercorn, J | 1 |
| Herndon, J | 1 |
| Kornblith, AB | 1 |
| Peters, W | 9 |
| Ahles, T | 1 |
| Schwartz, G | 2 |
| Shpall, E | 3 |
| Holland, J | 1 |
| Winer, E | 2 |
| Konoplev, S | 1 |
| Buchholz, TA | 1 |
| Smith, T | 1 |
| Anderlini, P | 1 |
| Cristofanilli, M | 1 |
| Ewend, MG | 1 |
| Brem, S | 1 |
| Gilbert, M | 1 |
| Goodkin, R | 1 |
| Penar, PL | 1 |
| Varia, M | 1 |
| Cush, S | 1 |
| Carey, LA | 1 |
| Weydert, CJ | 1 |
| Zhang, Y | 1 |
| Waugh, TA | 1 |
| Teoh, ML | 1 |
| Andringa, KK | 1 |
| Aykin-Burns, N | 1 |
| Spitz, DR | 1 |
| Stewart, DJ | 1 |
| Maroun, JA | 1 |
| Young, V | 1 |
| Crook, AF | 1 |
| Hopkins, HS | 1 |
| Yan, RC | 1 |
| Richard, MT | 1 |
| Hugenholtz, H | 1 |
| Bélanger, R | 1 |
| Heringer, R | 1 |
| DiBella, NJ | 1 |
| Garfield, D | 1 |
| Fink, K | 1 |
| Anderson, P | 1 |
| Speer, J | 1 |
| Massner, B | 1 |
| Voss, I | 1 |
| Queisser, W | 1 |
| Drings, P | 1 |
| Fritze, D | 1 |
| Westerhausen, M | 1 |
| Veronesi, A | 1 |
| Tirelli, U | 1 |
| Galligioni, E | 1 |
| Trovò, MG | 1 |
| Crivellari, D | 1 |
| Donatella Magri, M | 1 |
| Roncadin, M | 1 |
| Tumolo, S | 1 |
| Grigoletto, E | 1 |
| Falkson, G | 1 |
| Falkson, HC | 1 |
| Thel, MC | 1 |
| Ciaccia, D | 1 |
| Corey, GR | 1 |
| Ogawa, M | 1 |
| Mukaiyama, T | 1 |
| Antman, K | 4 |
| Ayash, L | 3 |
| Elias, A | 5 |
| Wheeler, C | 2 |
| Mazanet, R | 1 |
| Tepler, I | 1 |
| Schnipper, LE | 1 |
| Frei, E | 4 |
| Dicke, KA | 1 |
| Hood, DL | 1 |
| Hanks, S | 1 |
| Vaughan, M | 1 |
| Fulbright, L | 1 |
| Dicke, JA | 1 |
| Arneson, M | 1 |
| Blumenschein, G | 1 |
| Rabinowitz, J | 2 |
| Stuart, AR | 1 |
| Kalaycioglu, M | 1 |
| Kavuru, M | 1 |
| Tuason, L | 1 |
| Bolwell, B | 2 |
| Saez, RA | 1 |
| Slease, RB | 1 |
| Selby, GB | 1 |
| Strnad, C | 1 |
| Epstein, RB | 1 |
| Confer, DL | 1 |
| Stemmer, SM | 4 |
| Stears, JC | 2 |
| Burton, BS | 1 |
| Simon, JH | 2 |
| Gerson, SL | 3 |
| Berger, SJ | 1 |
| Varnes, ME | 1 |
| Donovan, C | 1 |
| Dufton, C | 2 |
| Meyers, S | 1 |
| Fisher, JH | 1 |
| Stephens, JK | 1 |
| Meisenberg, B | 1 |
| Kurtzberg, J | 1 |
| Bast, RC | 2 |
| Khawly, JA | 1 |
| Rubin, P | 2 |
| Petros, W | 1 |
| Jaffe, GJ | 1 |
| Rosenfeld, CS | 1 |
| LeFever, A | 1 |
| Taylor, R | 1 |
| List, A | 1 |
| Fay, J | 1 |
| Collins, R | 1 |
| Andrews, F | 1 |
| Pallansch, P | 1 |
| Resta, D | 1 |
| Levitt, D | 1 |
| Nemunaitis, J | 1 |
| Del Bufalo, D | 1 |
| Biroccio, A | 1 |
| Soddu, S | 1 |
| Laudonio, N | 1 |
| D'Angelo, C | 1 |
| Sacchi, A | 1 |
| Zupi, G | 1 |
| Strumberg, D | 1 |
| Harstrick, A | 1 |
| Doll, K | 1 |
| Hoffmann, B | 1 |
| Seeber, S | 1 |
| Deisseroth, AB | 1 |
| Holmes, F | 1 |
| Hortobagyi, G | 1 |
| Champlin, R | 2 |
| Purdy, MH | 2 |
| Merouani, A | 1 |
| Archer, PG | 1 |
| Schrier, RW | 1 |
| Hecht, JR | 1 |
| Lembo, T | 1 |
| Chap, L | 2 |
| Woo, MH | 1 |
| Ippoliti, C | 1 |
| Bruton, J | 1 |
| Mehra, R | 1 |
| Przepiorka, D | 1 |
| Fruehauf, JP | 2 |
| Zonis, S | 2 |
| al-Bassam, M | 2 |
| Kyshtoobayeva, A | 2 |
| Dasgupta, C | 2 |
| Milovanovic, T | 2 |
| Parker, RJ | 2 |
| Buzaid, AC | 2 |
| Overmoyer, BA | 1 |
| Bolwell, BJ | 1 |
| Taylor, CW | 1 |
| Cagnoni, PJ | 6 |
| Mechling, BE | 1 |
| Ronk, B | 1 |
| Shpiner, R | 1 |
| Levine, M | 1 |
| Lill, M | 1 |
| Glaspy, J | 2 |
| Brown, MS | 1 |
| Sheeder, JL | 1 |
| Laughlin, MJ | 1 |
| McGaughey, DS | 1 |
| Crews, JR | 1 |
| Gockerman, J | 1 |
| Berry, D | 3 |
| Mills, L | 1 |
| Defusco, P | 1 |
| LeGrand, S | 1 |
| Dunbar, SE | 1 |
| Gilbert, CJ | 2 |
| Fehdrau, R | 1 |
| Cavanaugh, C | 1 |
| McKinstry, C | 1 |
| Stuart, A | 1 |
| Xu, X | 2 |
| Spiro, TP | 1 |
| Liu, L | 1 |
| Majka, S | 1 |
| Haaga, J | 1 |
| Hoppel, CL | 1 |
| Ingalls, ST | 1 |
| Pluda, JM | 1 |
| Willson, JK | 1 |
| Fleming, DR | 1 |
| Goldsmith, GC | 1 |
| Stevens, DA | 1 |
| Herzig, RH | 1 |
| Phillips, WP | 1 |
| Bearman, S | 1 |
| Cagnoni, P | 1 |
| Dix, S | 1 |
| Cord, M | 1 |
| Howard, S | 1 |
| Coon, J | 1 |
| Belt, R | 1 |
| Geller, R | 1 |
| Ara, G | 1 |
| Teicher, B | 1 |
| Bunnell, C | 1 |
| Richardson, P | 1 |
| Tew, K | 1 |
| Hu, WW | 4 |
| Negrin, RS | 3 |
| Stockerl-Goldstein, K | 1 |
| Johnston, LJ | 3 |
| Shizuru, JA | 2 |
| Wong, RM | 2 |
| Feiner, RH | 1 |
| Klein, JL | 1 |
| Rey, PM | 1 |
| Dansey, RD | 1 |
| Karanes, C | 3 |
| Du, W | 1 |
| Abella, E | 1 |
| Cassells, L | 2 |
| Hamm, C | 1 |
| Baynes, RD | 1 |
| Atkinson, K | 1 |
| Leemhuis, T | 1 |
| Hanania, E | 1 |
| Juttner, C | 1 |
| Tierney, K | 1 |
| Shizurn, JA | 1 |
| Weissman, IL | 1 |
| Bower, S | 1 |
| Baynes, R | 2 |
| Cao, TM | 1 |
| Taylor, TL | 1 |
| Rizk, NW | 1 |
| Steingrimsdottir, H | 1 |
| Gruber, A | 1 |
| Björkholm, M | 1 |
| Svensson, A | 1 |
| Hansson, M | 1 |
| Wang, MY | 1 |
| Arnold, AC | 1 |
| Vinters, HV | 1 |
| Glasgow, BJ | 1 |
| Damon, LE | 1 |
| Wolf, JL | 1 |
| Gold, E | 1 |
| Cecchi, GR | 1 |
| Irwin, D | 1 |
| Territo, I | 1 |
| Miller, W | 1 |
| Mason, JR | 1 |
| Linker, CA | 1 |
| Protheroe, AS | 1 |
| Pickard, C | 1 |
| Johnson, PW | 1 |
| Craddock, T | 1 |
| Shefta, J | 1 |
| Short, K | 1 |
| Lancaster, F | 1 |
| Selby, PJ | 1 |
| Henwood, J | 1 |
| Boylston, AW | 1 |
| Chandrasekar, PH | 1 |
| Abraham, OC | 1 |
| Alangaden, G | 1 |
| Chalasani, G | 1 |
| Abella, S | 1 |
| Gibbs, JP | 1 |
| Schabel, FM | 1 |
| Presant, CA | 3 |
| Klahr, C | 3 |
| Santala, R | 1 |
| Freund, M | 1 |
| Ostendorf, P | 1 |
| Waller, HD | 1 |
| Hill, GJ | 1 |
| Johnson, RO | 1 |
| Metter, G | 1 |
| Wilson, WL | 1 |
| Davis, HL | 1 |
| Grage, T | 1 |
| Fletcher, WS | 1 |
| Golomb, FM | 1 |
| Cruz, AB | 1 |
| Van Amburg, A | 1 |
| Slavik, M | 2 |
| Wasserman, TH | 1 |
| Carter, SK | 2 |
| Kolhouse, JF | 1 |
| Cheson, BD | 1 |
| Ungerleider, RS | 1 |
| Cufer, T | 1 |
| Kolaric, K | 1 |
| Cervek, J | 1 |
| Cerar, O | 1 |
| Halperin, EC | 1 |
| Vaughan, WP | 1 |
| Bierman, PJ | 1 |
| Reed, EC | 1 |
| Glenn, LD | 1 |
| Kessinger, A | 1 |
| Armitage, JO | 1 |
| Kanj, SS | 1 |
| Sharara, AI | 1 |
| Lange, OF | 1 |
| Scheef, W | 1 |
| Haase, KD | 1 |
| Korbut, T | 1 |
| Herman, TS | 2 |
| Teicher, BA | 4 |
| Holden, SA | 2 |
| Epelbaum, R | 1 |
| Liu, SD | 1 |
| Ford, JM | 1 |
| Hait, WN | 1 |
| Matlin, SA | 1 |
| Benz, CC | 1 |
| Eder, JP | 3 |
| Shea, TC | 1 |
| Weissman, L | 1 |
| Critchlow, J | 1 |
| Schryber, SM | 1 |
| Begg, C | 1 |
| Panella, TJ | 1 |
| White, JG | 1 |
| Hannun, YA | 1 |
| Greenberg, CS | 1 |
| Kaminer, LS | 1 |
| Williams, SF | 1 |
| Beschorner, J | 1 |
| O'Brien, S | 1 |
| Golick, J | 1 |
| Bitran, JD | 1 |
| Schoen, HD | 1 |
| Wendt, T | 1 |
| Souhami, R | 1 |
| Olsen, GA | 1 |
| Gockerman, JP | 1 |
| Moore, JO | 1 |
| Cathcart, KN | 1 |
| Wang, YY | 1 |
| Henner, WD | 2 |
| Shea, T | 2 |
| Schryber, S | 2 |
| Andersen, J | 2 |
| Come, S | 1 |
| Schnipper, L | 1 |
| Appelbaum, FR | 1 |
| Finberg, R | 1 |
| Wilmore, D | 1 |
| Yardumian, H | 1 |
| Marsh, JC | 1 |
| DeConti, RC | 1 |
| Hubbard, SP | 1 |
| Reyes, ES | 1 |
| Talley, RW | 2 |
| O'Bryan, RM | 2 |
| Gastesi, RA | 1 |
| Bonnet, JD | 1 |
| Brownlee, RW | 1 |
| Vaitkevicius, VK | 1 |
| Gottlieb, JA | 1 |
| Rivkin, SE | 1 |
| Spigel, SC | 1 |
| Hoogstraten, B | 1 |
| Delaney, FC | 1 |
| Singhakowinta, A | 1 |
| Ahmann, DL | 2 |
| Hahn, RG | 1 |
| Bisel, HF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours Using the Quadratic Phenotypic Optimization Platform (QPOP) and an Artificial Intelligence-based Platform (CURATE.AI)[NCT05381038] | Phase 1/Phase 2 | 10 participants (Anticipated) | Interventional | 2022-06-30 | Not yet recruiting | ||
| A Multi-Center Study of Paclitaxel/Cyclophosphamide and High Dose Melphalan/Etoposide With Autologous Progenitor Cell Transplantation for the Treatment of Inflammatory Breast Cancer[NCT00001507] | Phase 1 | 107 participants (Actual) | Interventional | 1996-07-12 | Completed | ||
| Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy[NCT01626352] | Phase 2 | 22 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Prevention Of Nephrotoxicity Following Allogeneic Bone Marrow Transplantation Using Urodilatin (Ularitide,Atrial Natriuretic Peptide) and Mannitol.[NCT00390624] | Phase 2 | 20 participants (Anticipated) | Interventional | 2003-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Defined as the time from date of first documented confirmed response to date of disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. Patients who begin further anticancer therapy prior to disease progression will be censored at the date of last tumor assessment prior to the start date of the anticancer therapy. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle and every 3 months thereafter until disease progression or relapse from complete response for up to 38 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 5.6 |
Disease response assessments will be performed using the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires a disappearance of all evidence of disease. (NCT01626352)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 7 |
A treatment-related adverse event was any untoward medical occurrence in a participant which was considered to have a relationship with the study drug (suspected to be possibly or probably related to the study drug per the Investigator's assessment). Adverse events were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and up to 30 days after last dose, projected 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 16 |
Overall response is the number of patients with observed complete or partial response (CR or PR) as assessed using the International Working Group (IMW) revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires disappearance of all evidence of disease. Partial response requires regression of measurable disease and no new sites. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter, projected 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 19 |
Defined as the time from Day 1 of study drug administration to date of death from any cause. (NCT01626352)
Timeframe: every 3 cycles during treatment and every 3 months thereafter until progression or death from any cause, projected 18 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 12.0 |
Defined as the time from first treatment until objective tumor progression, relapse from complete response, or death from any cause. Tumor response is defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 8.6 |
Defined as the time from date of first treatment to the date of first documented disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 10.5 |
8 reviews available for carmustine and Breast Neoplasms
| Article | Year |
|---|---|
[Treatment strategy to obtain cure for recurrent advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carbo | 1994 |
[Treatment strategy to obtain cure for recurrent advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carbo | 1994 |
Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Cyclophosph | 1993 |
Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Cyclophosph | 1993 |
High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Calif | 2000 |
High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Calif | 2000 |
Rationale for adjuvant chemotherapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carmustine; Cyclophosphamide; Cytarabine; Doxorubi | 1977 |
Rationale for adjuvant chemotherapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carmustine; Cyclophosphamide; Cytarabine; Doxorubi | 1977 |
Clinical comparison of the nitrosoureas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carmustine; Chemical Phenomena; C | 1975 |
Clinical comparison of the nitrosoureas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carmustine; Chemical Phenomena; C | 1975 |
High dose chemotherapy in solid tumours in adults.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marr | 1986 |
High dose chemotherapy in solid tumours in adults.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marr | 1986 |
Solid tumor chemotherapy: new drugs and horizons.
Topics: Antineoplastic Agents; Bleomycin; Breast Neoplasms; Carmustine; Doxorubicin; Drug Therapy, Combinati | 1974 |
Solid tumor chemotherapy: new drugs and horizons.
Topics: Antineoplastic Agents; Bleomycin; Breast Neoplasms; Carmustine; Doxorubicin; Drug Therapy, Combinati | 1974 |
An overview of the status of the nitrosoureas in other tumors.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Br | 1973 |
An overview of the status of the nitrosoureas in other tumors.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Br | 1973 |
28 trials available for carmustine and Breast Neoplasms
| Article | Year |
|---|---|
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2010 |
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2010 |
[Regional chemoinfusion and radiation therapy to patients with breast cancer metastases to the brain: preliminary results].
Topics: Adult; Angiography; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Breast Neoplasms; Car | 2011 |
[Regional chemoinfusion and radiation therapy to patients with breast cancer metastases to the brain: preliminary results].
Topics: Adult; Angiography; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Breast Neoplasms; Car | 2011 |
High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Comb | 2002 |
High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Comb | 2002 |
A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects.
Topics: Adult; Amifostine; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2004 |
A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects.
Topics: Adult; Amifostine; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2004 |
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2004 |
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2004 |
Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2004 |
Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2004 |
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Chemother | 2005 |
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Chemother | 2005 |
Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brea | 2005 |
Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brea | 2005 |
High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Component Remova | 2006 |
High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Component Remova | 2006 |
Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carmustine; Combi | 2007 |
Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carmustine; Combi | 2007 |
High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marro | 1994 |
High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marro | 1994 |
Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II o
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carmu | 1995 |
Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II o
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carmu | 1995 |
Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1993 |
Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1993 |
Long-term survival after autologous bone marrow transplantation for metastatic breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; | 1995 |
Long-term survival after autologous bone marrow transplantation for metastatic breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; | 1995 |
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1993 |
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1993 |
Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.
Topics: Adult; Bone Marrow; Breast Neoplasms; Busulfan; Carboplatin; Carmustine; Cyclophosphamide; Drug Admi | 1996 |
Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.
Topics: Adult; Bone Marrow; Breast Neoplasms; Busulfan; Carboplatin; Carmustine; Cyclophosphamide; Drug Admi | 1996 |
Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 1996 |
Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 1996 |
High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Car | 1997 |
High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Car | 1997 |
Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 1997 |
Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 1997 |
Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin | 1998 |
Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin | 1998 |
Clinical pharmacology of filgrastim following high-dose chemotherapy and autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1997 |
Clinical pharmacology of filgrastim following high-dose chemotherapy and autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1997 |
Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neopl | 1999 |
Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neopl | 1999 |
O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Biotransformation; Breast Neoplasms; Carmust | 1999 |
O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Biotransformation; Breast Neoplasms; Carmust | 1999 |
Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin | 2000 |
Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin | 2000 |
Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmu | 2000 |
Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmu | 2000 |
Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Weight; Breast Neoplas | 2002 |
Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Weight; Breast Neoplas | 2002 |
Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Topics: Adenocarcinoma; Adenoma, Islet Cell; Adolescent; Adrenal Gland Neoplasms; Adult; Alkylating Agents; | 1971 |
Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Topics: Adenocarcinoma; Adenoma, Islet Cell; Adolescent; Adrenal Gland Neoplasms; Adult; Alkylating Agents; | 1971 |
Clinical evaluation of 1,3-bis(2-chloroethyl)-nitrosourea (BCNU; NSC-409962) with fluoxymesterone (NSC-12165) in the treatment of solid tumors.
Topics: Breast Neoplasms; Carcinoma, Squamous Cell; Carmustine; Clinical Trials as Topic; Edema; Fluoxymeste | 1973 |
Clinical evaluation of 1,3-bis(2-chloroethyl)-nitrosourea (BCNU; NSC-409962) with fluoxymesterone (NSC-12165) in the treatment of solid tumors.
Topics: Breast Neoplasms; Carcinoma, Squamous Cell; Carmustine; Clinical Trials as Topic; Edema; Fluoxymeste | 1973 |
81 other studies available for carmustine and Breast Neoplasms
| Article | Year |
|---|---|
Microclaw Array Fabricated by Single Exposure of Femtosecond Airy Beam and Self-Assembly for Regulating Cell Migratory Plasticity.
Topics: Breast Neoplasms; Carmustine; Cell Line, Tumor; Cell Movement; Epithelial Cells; Female; Humans; MCF | 2023 |
Microclaw Array Fabricated by Single Exposure of Femtosecond Airy Beam and Self-Assembly for Regulating Cell Migratory Plasticity.
Topics: Breast Neoplasms; Carmustine; Cell Line, Tumor; Cell Movement; Epithelial Cells; Female; Humans; MCF | 2023 |
Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carc | 2016 |
Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carc | 2016 |
The diverse roles of glutathione-associated cell resistance against hypericin photodynamic therapy.
Topics: Anthracenes; Breast Neoplasms; Buthionine Sulfoximine; Carmustine; Cell Line, Tumor; Drug Resistance | 2017 |
The diverse roles of glutathione-associated cell resistance against hypericin photodynamic therapy.
Topics: Anthracenes; Breast Neoplasms; Buthionine Sulfoximine; Carmustine; Cell Line, Tumor; Drug Resistance | 2017 |
Enhancing the antitumor activity of adriamycin and ionizing radiation.
Topics: Antineoplastic Agents; Breast Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Combined Modal | 2009 |
Enhancing the antitumor activity of adriamycin and ionizing radiation.
Topics: Antineoplastic Agents; Breast Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Combined Modal | 2009 |
Comparison of influence of carmustine and new proline analog of nitrosourea on antioxidant system in breast carcinoma cells (MCF-7).
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2010 |
Comparison of influence of carmustine and new proline analog of nitrosourea on antioxidant system in breast carcinoma cells (MCF-7).
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2010 |
Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carm | 2010 |
Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carm | 2010 |
Carboplatin and docetaxel-induced acute pancreatitis: brief report.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmus | 2010 |
Carboplatin and docetaxel-induced acute pancreatitis: brief report.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmus | 2010 |
Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Biological Transport; Breast Neoplasms; Carmustine; Cell | 2013 |
Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Biological Transport; Breast Neoplasms; Carmustine; Cell | 2013 |
Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biopsy, Needle; Breast Neop | 2003 |
Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biopsy, Needle; Breast Neop | 2003 |
Upper lobe pulmonary fibrosis associated with high-dose chemotherapy containing BCNU for bone marrow transplantation.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Breast Neoplasms; Carmustine; Drug A | 2003 |
Upper lobe pulmonary fibrosis associated with high-dose chemotherapy containing BCNU for bone marrow transplantation.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Breast Neoplasms; Carmustine; Drug A | 2003 |
Interferon-gamma for delayed pulmonary toxicity syndrome resistant to steroids.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2003 |
Interferon-gamma for delayed pulmonary toxicity syndrome resistant to steroids.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2003 |
Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cyclophosphamid | 2003 |
Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cyclophosphamid | 2003 |
Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation.
Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantatio | 2003 |
Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation.
Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantatio | 2003 |
Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 2004 |
Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 2004 |
Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapy.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2005 |
Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapy.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2005 |
Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Cycl | 2005 |
Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Cycl | 2005 |
Increased oxidative stress created by adenoviral MnSOD or CuZnSOD plus BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) inhibits breast cancer cell growth.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Breast Neoplasms; Carmu | 2008 |
Increased oxidative stress created by adenoviral MnSOD or CuZnSOD plus BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) inhibits breast cancer cell growth.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Breast Neoplasms; Carmu | 2008 |
Feasibility study of combining metronidazole with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma, Sq | 1983 |
Feasibility study of combining metronidazole with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma, Sq | 1983 |
Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmu | 1984 |
Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmu | 1984 |
[Alternative treatment with carmustine, vindesine and tamoxifen in previously cytostaticly (VAC, FMC) treated patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carmustine; Drug Therapy, Combination; Female; | 1982 |
[Alternative treatment with carmustine, vindesine and tamoxifen in previously cytostaticly (VAC, FMC) treated patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carmustine; Drug Therapy, Combination; Female; | 1982 |
Third-line chemotherapy with mitomycin, vinblastine, and carmustine (BCNU) in refractory breast carcinoma: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carmustine; Drug Administratio | 1982 |
Third-line chemotherapy with mitomycin, vinblastine, and carmustine (BCNU) in refractory breast carcinoma: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carmustine; Drug Administratio | 1982 |
A five-drug combination in the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; | 1981 |
A five-drug combination in the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; | 1981 |
Clostridium septicum abscess in hepatic metastases: successful medical management.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1994 |
Clostridium septicum abscess in hepatic metastases: successful medical management.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1994 |
A marrow harvest procedure under local anesthesia.
Topics: Anesthesia, Local; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 1995 |
A marrow harvest procedure under local anesthesia.
Topics: Anesthesia, Local; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 1995 |
Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Forced Expirato | 1995 |
Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Forced Expirato | 1995 |
White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain; Breast Ne | 1994 |
White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain; Breast Ne | 1994 |
Combined depletion of O6-alkylguanine-DNA alkyltransferase and glutathione to modulate nitrosourea resistance in breast cancer.
Topics: Breast Neoplasms; Carmustine; Cell Line; Cell Survival; Drug Resistance; Ethylnitrosourea; Glutathio | 1994 |
Combined depletion of O6-alkylguanine-DNA alkyltransferase and glutathione to modulate nitrosourea resistance in breast cancer.
Topics: Breast Neoplasms; Carmustine; Cell Line; Cell Survival; Drug Resistance; Ethylnitrosourea; Glutathio | 1994 |
Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplat | 1993 |
Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplat | 1993 |
Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1996 |
Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1996 |
Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carmustine; Cell Line; Doxorubicin; Drug Resista | 1996 |
Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carmustine; Cell Line; Doxorubicin; Drug Resista | 1996 |
Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine | 1996 |
Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine | 1996 |
Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B | 1996 |
Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B | 1996 |
Positive selection and ex vivo expansion of hematopoietic progenitors as autografts for high-dose chemotherapy, potential importance in patients with bone metastases.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1995 |
Positive selection and ex vivo expansion of hematopoietic progenitors as autografts for high-dose chemotherapy, potential importance in patients with bone metastases.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1995 |
Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Comb | 1997 |
Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Comb | 1997 |
Headache, circumoral paresthesia, and facial flushing associated with high-dose carmustine infusion.
Topics: Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Ductal, Breast; Carmustine; Cytokine | 1997 |
Headache, circumoral paresthesia, and facial flushing associated with high-dose carmustine infusion.
Topics: Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Ductal, Breast; Carmustine; Cytokine | 1997 |
Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Breast Neoplasms; Buthionine Sul | 1997 |
Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Breast Neoplasms; Buthionine Sul | 1997 |
White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Brain; Brain Diseases; B | 1998 |
White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Brain; Brain Diseases; B | 1998 |
Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantat | 1998 |
Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantat | 1998 |
High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; | 1998 |
High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; | 1998 |
Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Buthionine Sulfoximine; Carmustine | 1998 |
Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Buthionine Sulfoximine; Carmustine | 1998 |
Dose-intensive chemotherapy for breast cancer with brain metastases: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carboplati | 1999 |
Dose-intensive chemotherapy for breast cancer with brain metastases: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carboplati | 1999 |
Acquired resistance to O6-benzylguanine plus chloroethylnitrosoureas in human breast cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1999 |
Acquired resistance to O6-benzylguanine plus chloroethylnitrosoureas in human breast cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1999 |
High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmustine; Ci | 1999 |
High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmustine; Ci | 1999 |
Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
Topics: Adult; Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 1999 |
Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
Topics: Adult; Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 1999 |
A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Mal | 1999 |
A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Mal | 1999 |
Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Breast Neoplasms; Carmustine; Cell Survival; Cisp | 2000 |
Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Breast Neoplasms; Carmustine; Cell Survival; Cisp | 2000 |
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.
Topics: Adjuvants, Pharmaceutic; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; B | 2000 |
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.
Topics: Adjuvants, Pharmaceutic; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; B | 2000 |
Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Arrhythm | 2000 |
Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Arrhythm | 2000 |
Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot | 2000 |
Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot | 2000 |
Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Carmu | 2000 |
Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Carmu | 2000 |
Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blindness; Breast Neoplasms; Carcinoma, Ductal, Brea | 2000 |
Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blindness; Breast Neoplasms; Carcinoma, Ductal, Brea | 2000 |
Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue.
Topics: Amino Acid Sequence; Antineoplastic Agents, Alkylating; Bone Marrow Purging; Breast Neoplasms; Carci | 2000 |
Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue.
Topics: Amino Acid Sequence; Antineoplastic Agents, Alkylating; Bone Marrow Purging; Breast Neoplasms; Carci | 2000 |
Low infectious morbidity after intensive chemotherapy and autologous peripheral blood progenitor cell transplantation in the outpatient setting for women with breast cancer.
Topics: Adult; Aged; Ambulatory Care; Ambulatory Care Facilities; Anti-Infective Agents; Antibiotic Prophyla | 2001 |
Low infectious morbidity after intensive chemotherapy and autologous peripheral blood progenitor cell transplantation in the outpatient setting for women with breast cancer.
Topics: Adult; Aged; Ambulatory Care; Ambulatory Care Facilities; Anti-Infective Agents; Antibiotic Prophyla | 2001 |
Amphotericin B induction of sensitivity to adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) plus cyclophosphamide in human neoplasia.
Topics: Adult; Aged; Amphotericin B; Breast Neoplasms; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resis | 1977 |
Amphotericin B induction of sensitivity to adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) plus cyclophosphamide in human neoplasia.
Topics: Adult; Aged; Amphotericin B; Breast Neoplasms; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resis | 1977 |
[(Meningeal carcinomatosis in patients with breast cancer)].
Topics: Adult; Aged; Breast Neoplasms; Carmustine; Female; Humans; Injections, Spinal; Mastectomy; Meningeal | 1979 |
[(Meningeal carcinomatosis in patients with breast cancer)].
Topics: Adult; Aged; Breast Neoplasms; Carmustine; Female; Humans; Injections, Spinal; Mastectomy; Meningeal | 1979 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962) and cyclophosphamide therapy of drug-resistant metastatic breast carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Ascites; Bone Neoplasms; Breast Neoplasms; Carmustine; | 1977 |
Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962) and cyclophosphamide therapy of drug-resistant metastatic breast carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Ascites; Bone Neoplasms; Breast Neoplasms; Carmustine; | 1977 |
Clinical studies with nitrosoureas in various solid tumors.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Carmustine; Female; Genital Neoplasms, F | 1976 |
Clinical studies with nitrosoureas in various solid tumors.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Carmustine; Female; Genital Neoplasms, F | 1976 |
Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC 409462), and cyclophosphamide in refractory adenocarcinoma of the breast and other tumors.
Topics: Adenocarcinoma; Adolescent; Aged; Breast Neoplasms; Carcinoma, Squamous Cell; Carmustine; Cyclophosp | 1976 |
Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC 409462), and cyclophosphamide in refractory adenocarcinoma of the breast and other tumors.
Topics: Adenocarcinoma; Adolescent; Aged; Breast Neoplasms; Carcinoma, Squamous Cell; Carmustine; Cyclophosp | 1976 |
Clinical trials referral resource. High priority trials--III. Breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carci | 1992 |
Clinical trials referral resource. High priority trials--III. Breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carci | 1992 |
Combination of 5-fluorouracil, imidazole carboxamide, BCNU and prednisolone (FIB-P) as a salvage chemotherapy in heavily pretreated breast cancer patients.
Topics: Aminoimidazole Carboxamide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmus | 1992 |
Combination of 5-fluorouracil, imidazole carboxamide, BCNU and prednisolone (FIB-P) as a salvage chemotherapy in heavily pretreated breast cancer patients.
Topics: Aminoimidazole Carboxamide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmus | 1992 |
Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1992 |
Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1992 |
High-dose hydroxyurea in autologous bone marrow transplantation: a promising "new" agent.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplanta | 1992 |
High-dose hydroxyurea in autologous bone marrow transplantation: a promising "new" agent.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplanta | 1992 |
Myocardial ischemia associated with high-dose carmustine infusion.
Topics: Adult; Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1991 |
Myocardial ischemia associated with high-dose carmustine infusion.
Topics: Adult; Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1991 |
Palliative radio-chemotherapy with ifosfamide and BCNU for breast cancer patients with cerebral metastases. A 5-year experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carm | 1990 |
Palliative radio-chemotherapy with ifosfamide and BCNU for breast cancer patients with cerebral metastases. A 5-year experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carm | 1990 |
Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Brea | 1991 |
Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Brea | 1991 |
Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carboplatin; Carmustine; Drug Resistance; Drug Scr | 1991 |
Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carboplatin; Carmustine; Drug Resistance; Drug Scr | 1991 |
Modulation of resistance to alkylating agents in cancer cell by gossypol enantiomers.
Topics: Alkylating Agents; Animals; Breast Neoplasms; Buthionine Sulfoximine; Carcinoma 256, Walker; Carmust | 1991 |
Modulation of resistance to alkylating agents in cancer cell by gossypol enantiomers.
Topics: Alkylating Agents; Animals; Breast Neoplasms; Buthionine Sulfoximine; Carcinoma 256, Walker; Carmust | 1991 |
High-dose thiotepa alone and in combination regimens with bone marrow support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1990 |
High-dose thiotepa alone and in combination regimens with bone marrow support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1990 |
Platelets acquire a secretion defect after high-dose chemotherapy.
Topics: Adenosine Triphosphate; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelet Disord | 1990 |
Platelets acquire a secretion defect after high-dose chemotherapy.
Topics: Adenosine Triphosphate; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelet Disord | 1990 |
High dose chemotherapy with autologous hematopoietic stem cell support in the treatment of refractory stage IV breast carcinoma.
Topics: Adult; Breast Neoplasms; Carmustine; Cell Survival; Cyclophosphamide; Dose-Response Relationship, Dr | 1989 |
High dose chemotherapy with autologous hematopoietic stem cell support in the treatment of refractory stage IV breast carcinoma.
Topics: Adult; Breast Neoplasms; Carmustine; Cell Survival; Cyclophosphamide; Dose-Response Relationship, Dr | 1989 |
[The effect of chemotherapy on survival time in advanced breast carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carmustine; Combined Mo | 1989 |
[The effect of chemotherapy on survival time in advanced breast carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carmustine; Combined Mo | 1989 |
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1988 |
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1988 |
Preclinical studies and clinical correlation of the effect of alkylating dose.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Breast Neoplasms; Carmustine; Cell Survival; Cisp | 1988 |
Preclinical studies and clinical correlation of the effect of alkylating dose.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Breast Neoplasms; Carmustine; Cell Survival; Cisp | 1988 |
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Trans | 1986 |
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Trans | 1986 |
Hammering away at solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carmu | 1987 |
Hammering away at solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carmu | 1987 |
High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1987 |
High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1987 |
Response of advanced breast cancer to two dosage regiments of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Topics: Adult; Age Factors; Aged; Breast Neoplasms; Carmustine; Female; Gastrointestinal Diseases; Humans; M | 1973 |
Response of advanced breast cancer to two dosage regiments of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Topics: Adult; Age Factors; Aged; Breast Neoplasms; Carmustine; Female; Gastrointestinal Diseases; Humans; M | 1973 |
Proceedings: Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. A Southwest Cancer Chemotherapy study Group study.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Carmustine; Cyclohexanes; Doxorubicin; Female; Humans | 1974 |
Proceedings: Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. A Southwest Cancer Chemotherapy study Group study.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Carmustine; Cyclohexanes; Doxorubicin; Female; Humans | 1974 |
Evaluation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the management of patients with advanced breast cancer.
Topics: Administration, Oral; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carmustine; Female | 1972 |
Evaluation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the management of patients with advanced breast cancer.
Topics: Administration, Oral; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carmustine; Female | 1972 |
The phase II study: some reflections, particularly concerning disseminated breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carmustine; Cyclohexanes; Cyclophosphamide; Female; Fluorou | 1972 |
The phase II study: some reflections, particularly concerning disseminated breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carmustine; Cyclohexanes; Cyclophosphamide; Female; Fluorou | 1972 |